Lexeo Therapeutics (LXEO) Profit After Tax (2022 - 2026)

Lexeo Therapeutics (LXEO) has 5 years of Profit After Tax data on file, last reported at -$20.2 million in Q1 2026.

• For the quarter ending Q1 2026, Profit After Tax rose 38.16% year-over-year to -$20.2 million; the trailing twelve-month figure through Mar 2026 stood at -$87.6 million (up 19.88% YoY), and the FY2025 full-year result was -$100.0 million, down 1.7% from the prior year.
• Profit After Tax advanced to -$20.2 million in Q1 2026, from -$21.0 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of -$13.4 million in Q2 2023 to a low of -$32.7 million in Q1 2025.
• A 5-year average of -$21.1 million and a median of -$20.3 million in 2025 frame the typical range for Profit After Tax.
• Across the five-year window, Profit After Tax tumbled 82.65% in 2024 and jumped 38.16% in 2026, its largest moves.
• Tracing LXEO's Profit After Tax over 5 years: stood at -$14.6 million in 2022, then advanced by 2.79% to -$14.2 million in 2023, then tumbled by 82.65% to -$25.9 million in 2024, then advanced by 18.99% to -$21.0 million in 2025, then grew by 3.83% to -$20.2 million in 2026.
• Business Quant data shows LXEO's Profit After Tax at -$20.2 million in Q1 2026, -$21.0 million in Q4 2025, and -$20.3 million in Q3 2025.